Please enable Javascript
Ghassan Abou-Alfa, MD
Articles by Ghassan Abou-Alfa, MD
PROOF 301: Infigratinib Versus Gemcitabine Plus Cisplatin for CCA With FGFR2 Rearrangements
Ghassan Abou-Alfa, MD
Bile Duct Cancer
|
March 13, 2025
Dr. Abou-Alfa describes the promising outcomes of infigratinib and delves into further research on FGFR alterations in CCA.
View More